Trial Profile

A Trial Evaluating the Pharmacodynamic Response of NN1250 at Steady State Conditions in Subjects With Type 1 Diabetes.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 11 Oct 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Insulin degludec (Primary) ; Insulin glargine
Indications Type 1 diabetes mellitus
Focus Pharmacodynamics
Sponsors Novo Nordisk

Most Recent Events

12 Jun 2012 Results of this and one other trial presented at the 72nd Annual Scientific Sessions of the American Diabetes Association.
08 Dec 2011 Results presented at the 21st World Diabetes Congress.
16 Sep 2011 Results presented at the 47th Annual Meeting of the European Association for the Study of Diabetes.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com